Valion Bio appoints Dean Zikria as Interim CEO; board leadership reshuffled

Valion Bio, Inc.

Dean Zikria appointed Interim CEO effective Sept 22, 2026; he remains on the Board.
Zikria earns $23,333/month, 50k RSUs (plus 50k more if plan enlarged), and potential cash bonus on strategic transaction.
Sheryle Bolton resigned from Board Sept 17, 2026; Thomas Jensen named Board Chair and Compensation Committee Chair.
Jared Malbin appointed Audit and Risk Committee Chair; Zikria removed from audit, comp, and governance committees.
Company emphasizes advancing Entolimod and evaluating strategic, commercial, and government opportunities.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.